New drug therapies to treat serious and life-threatening diseases would be reviewed more quickly under draft regulations under consideration by China’s Center for Drug Evaluation (CDE). The proposed guidelines would allow for priority review and conditional approval of pharmaceuticals deemed to have... Read More
Pushing to increase the ability of China’s medical institutions to conduct much-needed medical device and drug trials without sacrificing safety or quality, the National Medical Products Administration added more than 150 medical institutions to the list of those certified to host clinical... Read More
Chronic health disorders linked to obesity, smoking, high salt intake, and pollution are mounting in China, as Asia’s largest economy grapples with the burdens of rapid growth and affluence. A new study published in the Lancet finds chronic illnesses including stroke, hypertension,... Read More
With the goal of raising the quality and accessibility of its healthcare system to a level commensurate with its position as the world’s second-largest economy, the Chinese government has in the past five years doubled the money it pours into public hospitals... Read More
Less than two years after China first began to prioritize the diagnosis and treatment of rare diseases, the government is ordering hospitals to gather copious data on cases in a bid to promote their diagnosis and treatment. The notification in November 2019... Read More
Moving to improve the safety of clinical trials, China’s Center for Drug Evaluation (CDE) has drafted new regulations on the timing, duration, and manner in which such trials are conducted. Under the new regulations, clinical trials would need to be initiated within... Read More
China’s National Medical Products Administration (NMPA) is seeking public comments on new regulations it is drafting on drug registration, drug distribution, and manufacturing. The new regulations, updated in October by the Ministry of Justice, reflect changes made to the Drug Administration Law... Read More
China’s ambitious campaign to expand healthcare coverage and access to innovative drugs is making its pharmaceutical market an increasingly key source of growth for foreign firms. But even as the more than $135 billion pharmaceutical markets in the Asian giant surpasses that... Read More
Spending on cancer drugs is dominating health spending in China, with hospitals in 2018 purchasing more cancer and immunomodulatory drugs than anti-infective drugs for the first time ever. According to data from the China Pharmaceutical Association (CPA), anti-tumor and immunomodulatory treatments represented... Read More
This article was originally published on Medtech Intelligence. Precision medicine, an emerging toolkit of ways to better understand the complex mechanisms underlying a patient’s health, disease, or condition, and to better predict which treatments will be most effective, has grown unevenly outside... Read More